🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the fight against superbug strains of the pathogen, according to scientists.

An International Health Concern

Cases of gonorrhoea are increasing worldwide, with figures suggesting in excess of 82 million new cases per year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Health officials are increasingly worried about the surge in drug-resistant strains. The global health body has classified it as a "critical concern". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Receive Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This treatment, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This authorization marks a major breakthrough in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Outcomes and Worldwide Availability

According to findings published in a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves a dual-drug approach. The research enrolled hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to register and commercialise the drug in a wide range of developing nations.

Doctors on the front lines have shared optimism. The availability of a one-pill regimen of this kind is hailed as a "critical tool" for managing the epidemic. This is viewed as vital to lessen the impact of the illness for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.